Herein, we showed that 77.78% (42/54) patients with HBV-related compensate cirrhosis had undetectable serum HBV DNA (<50 IU/mL) at 48 weeks post-PEG-IFN-α-2b therapy. This evidence concerns the gene IFNA2 and Cirrhosis.